IL-17F、IL-36β及CGRP1与中重度斑块型银屑病患者阿达木单抗治疗有效应答的相关性
Correlation of IL-17F,IL-36β and CGRP1 with Effective Response to Adalimumab Therapy in Patients with Moderate-to-severe Plaque Psoriasis
任雪飞 1张艳奇 1孙晓圆1
作者信息
- 1. 安阳市第三人民医院(河南安阳 455000)
- 折叠
摘要
目的 分析IL-17F、IL-36β及CGRP1与中重度斑块型银屑病患者阿达木单抗治疗有效应答的相关性.方法 经安阳市第三人民医院伦理学会批准选择医院2020年8月1日至2022年8月1日收治的中重度斑块型银屑病患者68例.使用阿达木单抗治疗,在治疗前后检测IL-17F、IL-36β及CGRP1水平,并随访评定有效应答,分析其相关性,收集其不良反应.结果 治疗前中度患者IL-17F、IL-36β及CGRP 1水平低于重度患者(P＜0.05).治疗后中度患者IL-17F、IL-36β及CGRP1水平低于重度患者(P＜0.05).有效应答患者为50例,未应答患者18例.其中未应答患者后IL-17F、IL-36β、CGRP1水平在治疗前后明显高于有效应答患者(P＜0.05).IL-17F、IL-36β、CGRP1水平影响患者有效应答.其水平越高,有效应答率越低,呈负相关(P＜0.05).本次治疗出现了瘙痒(2例)、疼痛(1例)、感染(1例)、红肿(2例)不良反应.结论 IL-17F、IL-36β及CGRP1水平影响中重度斑块型银屑病患者阿达木单抗治疗有效应答,其水平越高,有效应答率越低,建议在治疗前密切关注.
Abstract
Objective To analyze the correlation of interleukin-17F(IL-17F),interleukin-36β(IL-36β)and calcitonin gene-related peptide 1(CGRP1)with effective response to adalimumab therapy in patients with moderate-to-severe plaque psoriasis.Methods With the approval of the Anyang Third People's Hospital Ethics Committee,68 patients with moderate-to-severe plaque psoriasis in our hospital from August 1,2020 to August 1,2022 were enrolled,and all patients received adalimumab therapy.Serum levels of IL-17F,IL-36β and CGRP1 were detected at the baseline and end of treatment,and the treatment response rate was evaluated during the follow-up period.Then the correlation of three serum indicators with treat-ment response was discussed,meantime,the adverse reaction was recorded.Results Baseline IL-17F,IL-36[3 and CGRP1 levels of moderate patients were lower than those of severe patients(P＜0.05),and the post-treatment IL-17F,IL-36β and CGRP1 levels of moderate patients were still lower than those of severe patients(P＜0.05).Adalimumab treatment was ef-fective in 50 patients and ineffective in 18 patients.Serum levels of IL-17F,IL-36β and CGRP1 at the baseline and end of treatment in patients without response were significantly higher than those in patients with effective response(P＜0.05).IL-17F,IL-36β and CGRP1 levels cause a negative impact on the effective response to adalimumab therapy in patients,indica-ting that patients with higher levels suffered a lower response rate(P＜0.05).There were 2 cases of pruritus,1 case of pain,1 case of infection and 2 cases of redness and swelling.Conclusion IL-17F,IL-36β and CGRP1 levels have impact on effective response to adalimumab therapy in patients with moderate-to-severe plaque psoriasis,and patients with elevated levels of three indicators have low response rate,so the pre-treatment examination is of great value.
关键词
IL-17F/IL-36β/CGRP1/中重度斑块型/银屑病/阿达木单抗/有效应答/相关性Key words
IL-17F/IL-36β/CGRP1/Moderate-to-severe plaque type/Psoriasis/Adalimumab/Effective response/Corre-lation引用本文复制引用
出版年
2024
NETL
NSTL
万方数据